Literature DB >> 20206690

Selective Glucocorticoid Receptor modulators.

Karolien De Bosscher1.   

Abstract

The ancient two-faced Roman god Janus is often used as a metaphor to describe the characteristics of the Glucocorticoid Receptor (NR3C1), which exhibits both a beneficial side, that serves to halt inflammation, and a detrimental side responsible for undesirable effects. However, recent developments suggest that the Glucocorticoid Receptor has many more faces with the potential to express a range of different functionalities, depending on factors that include the tissue type, ligand type, receptor variants, cofactor surroundings and target gene promoters. This behavior of the receptor has made the development of safer ligands, that trigger the expression program of only a desirable subset of genes, a real challenge. Thus more knowledge-based fundamental research is needed to ensure the design and development of selective Glucocorticoid Receptor modulators capable of reaching the clinic. Recent advances in the characterization of novel selective Glucocorticoid Receptor modulators, specifically in the context of anti-inflammatory strategies, will be described in this review. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20206690     DOI: 10.1016/j.jsbmb.2010.02.027

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  48 in total

1.  Transcription factor binding predictions using TRAP for the analysis of ChIP-seq data and regulatory SNPs.

Authors:  Morgane Thomas-Chollier; Andrew Hufton; Matthias Heinig; Sean O'Keeffe; Nassim El Masri; Helge G Roider; Thomas Manke; Martin Vingron
Journal:  Nat Protoc       Date:  2011-11-03       Impact factor: 13.491

2.  Compound A, a selective glucocorticoid receptor agonist, inhibits immunoinflammatory diabetes, induced by multiple low doses of streptozotocin in mice.

Authors:  T Saksida; M Vujicic; I Nikolic; I Stojanovic; G Haegeman; S Stosic-Grujicic
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

3.  Improving the diagnosis and treatment of CRPS: insights from a clinical immunologist's personal experience with an underrecognized neuroinflammatory disorder.

Authors:  Karen E Binkley
Journal:  J Neuroimmune Pharmacol       Date:  2012-05-16       Impact factor: 4.147

Review 4.  Minireview: new molecular mediators of glucocorticoid receptor activity in metabolic tissues.

Authors:  Rucha Patel; Jasmine Williams-Dautovich; Carolyn L Cummins
Journal:  Mol Endocrinol       Date:  2014-04-25

Review 5.  Structural dynamics, intrinsic disorder, and allostery in nuclear receptors as transcription factors.

Authors:  Vincent J Hilser; E Brad Thompson
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

6.  Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.

Authors:  Christian Harcken; Doris Riether; Pingrong Liu; Hossein Razavi; Usha Patel; Thomas Lee; Todd Bosanac; Yancey Ward; Mark Ralph; Zhidong Chen; Donald Souza; Richard M Nelson; Alison Kukulka; Tazmeen N Fadra-Khan; Ljiljana Zuvela-Jelaska; Mita Patel; David S Thomson; Gerald H Nabozny
Journal:  ACS Med Chem Lett       Date:  2014-11-20       Impact factor: 4.345

7.  New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it.

Authors:  Heather A Ferris; C Ronald Kahn
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

8.  Dexamethasone-mediated changes in adipose triacylglycerol metabolism are exaggerated, not diminished, in the absence of a functional GR dimerization domain.

Authors:  Donald J Roohk; Smita Mascharak; Cyrus Khambatta; Ho Leung; Marc Hellerstein; Charles Harris
Journal:  Endocrinology       Date:  2013-03-14       Impact factor: 4.736

9.  Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells.

Authors:  Megan E Cavet; Karen L Harrington; Keith W Ward; Jin-Zhong Zhang
Journal:  Mol Vis       Date:  2010-09-02       Impact factor: 2.367

10.  Δ-9,11 modification of glucocorticoids dissociates nuclear factor-κB inhibitory efficacy from glucocorticoid response element-associated side effects.

Authors:  Andreas R Baudy; Erica K M Reeves; Jesse M Damsker; Christopher Heier; Lindsay M Garvin; Blythe C Dillingham; John McCall; Sree Rayavarapu; Zuyi Wang; Jack H Vandermeulen; Arpana Sali; Vanessa Jahnke; Stephanie Duguez; Debra DuBois; Mary C Rose; Kanneboyina Nagaraju; Eric P Hoffman
Journal:  J Pharmacol Exp Ther       Date:  2012-06-28       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.